SIS to consolidate Indian operations
Surgical Information Systems (SIS) to consolidate its Indian
operations based at Hyderabad and signs up with new clients globally to be
supported from its India development cum support centre.
Himanshu Ubale, Head, SIS India in a statement said the Indian
development centre would continue to focus on software development and quality
assurance for SIS' over 200 customers globally. SIS India is our strategic
product development centre.
The new wins include Catholic Health East, which chose SIS as a
solution partner for automated intelligence in surgery. Catholic Health East is
one of the largest healthcare services provider. The company also bagged mandate
from Sick Kids based in Toronto, Canada, that delivers medical treatment and
care for children.
(Ref : Express Pharma Pulse Dated March 3, 2005)
Vascular Concepts to launch combination drug eluting stent
Bangalore based Vascular Concepts, a leading company engaged in
the design, development and manufacture of endovascular medical devices, plans
to launch combination drug eluting stent soon. Speaking to Express Pharma Pulse,
Swaminathan M Jayaraman, chief executive office, Vascular Concepts, said that
the combination drug eluting stent shall enable to target different cells at the
The group develops its own technology, based on its extensive
patent portfolio of intellectual property, which includes 28 patents in the
United States, he added.
The products are developed at the company's R&D centre in
Bangalore, which is equipped with a world-class cleanroom. The company has
manufacturing collaboration with Eucatech AG of Germany where all its devices
are manufactured to the European standards.
Vascular Concepts has developed first generation stainless steel
coronary stent systems ProLink LP and ProLink SV for smaller coronary vessels.
The second generation of products include a state-of-the-art
nanotechnology coating on stents, which was developed between Vascular Concepts
and a US company, which has granted an exclusive worldwide license on platinum,
activated coronary stent system Propass.
Propass is awaiting approval and later will hit the market soon,
said Jayaraman. The other ancillary technology products include peripheral
stents Prostar; angioplasty balloon catheters Speed and valvuplasty balloon
The company has recently introduced its drug eluting coronary
stent systems Pronova. Pronova, a state-of-the-art siroliums eluting stent, is
proven to reduce restenosis (reoccurrence of blockage) in coronary vessels. The
technology developed in Bangalore has been evaluated in some the premier
hospitals in the country.
The company's patented drug eluting
stents, with a combination
of siroliums and cyclosporine, are undergoing preclinical trials inthe
Netherlands. Clinical trials are planned in Europe in the next few months.
Vascular Concepts' coronary stents enjoys 25 percent market
share and it expects to achieve similar success with its new drug eluting stents
said, Jayaraman. The company has completed a series of clinical trials on
ProNova stents on a patient base of over 1000, the results of which were
presented at CAD 2004 in Mumbai by four leading cardiologists in India.
Vascular Concepts, a Rs 35 crore company, expects to achieve a
growth of around 60 to 70 per cent in the coming years.
(Ref : Express Pharma Pulse Dated March 10, 2005)